hHSC_Iso4_ADCF_SeViPS2 (Phönix)
MHHi001-A
General
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | neonate |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | N/A |
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46,XX
Karyotyping method:
R-banding
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA4564585 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | No |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent expressly permit collection of genetic information? | Yes |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does consent permit access to medical records of the donor? | No |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | MHH Ethikkommission |
| Approval number | 1303-2012 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | MHH Ethikkommission |
| Approval number | 1303-2012 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
iPSC Derivation
General |
|
| Source cell type |
Synonyms
|
| Source cell origin |
Any hematopoietic stem cell that is part of a umbilical cord blood.
|
| Source cell type (free text) | CD34 positive human cord blood hematopoietic stem cells (CD34+hCBHSCs) |
| Age of donor (at collection) | neonate |
| Collected in | 2014 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
iPSC Culture Conditions
| Surface coating | Vitronectin, Synthemax, Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
ReLeSR, Versene
|
| Medium |
Other medium:
Base medium: iPS Brew, mTeSR E8
Main protein source: Serum concentration: % |
iPSC Characterisation
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| TRA 1-60 |
Yes |
|
||||
| NANOG |
Yes |
|
||||
| SSEA-3 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
Differentiation Potency
In vitro spontaneous differentiation
In vitro spontaneous differentiation
| Marker | Expressed |
| sarcomeric Actinin |
Yes |
| cTroponin T |
Yes |
| Desmin |
Yes |
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
46,XX
Passage number: 39
|
Other Genotyping (iPSC Line) |
|
Login to share your feedback, experiences or results with the research community.